What Furantin 100 Treats: Main Uses and Benefits

Furantin 100 (nitrofurantoin) is generally used to address bacterial infections that cause conditions characterized by episodic or fluctuating manifestations in the lower urinary tract. The medication is primarily applied in clinical settings that involve acute or unstable symptom patterns related to urinary tract infections (UTIs) due to susceptible bacteria, including acute cystitis. It is also commonly used for the prophylaxis (prevention) of recurrent UTIs. Specifically, it is indicated for urinary tract infections.

The main therapeutic role of Furantin 100 is easing symptoms related to heightened physiological activity, such as the painful or burning sensation during urination and the frequent, urgent need to go. This supportive use helps maintain a sense of stability when symptoms are more noticeable, assisting with maintaining functional stability during episodes of discomfort. Patients often describe the benefit as:

“The medication supports patients during difficult episodes by easing distress and may help patients cope more steadily with symptom fluctuations.”

Quick Fact

Used for Managing Urination Discomfort (Dysuria)

Who Can and Cannot Use Furantin 100?

Eligibility for Furantin 100 (nitrofurantoin) is strictly defined by regulatory documents based on patient age, organ function, and specific medical history. These official rules establish which populations are permitted to use the medicine and which groups are absolutely prohibited.

Who is Prohibited from Use (Contraindications)

Furantin 100 must not be used in the following populations:

• Significant Renal Impairment: Patients with Anuria, Oliguria, or Creatinine Clearance (CrCl) less than 60 mL/minute (per FDA/NZ labels) or eGFR less than 45 mL/minute (per UK/EMA labels).
• Specific Hepatic History: Patients with a history of cholestatic jaundice or hepatic dysfunction linked to prior nitrofurantoin use.
• Age and Gestation: Neonates and infants under one to three months of age, and pregnant patients at term (38 to 42 weeks).
• Genetic/Allergy: Patients with known hypersensitivity to nitrofurantoin or any nitrofuran derivatives, or those with G6PD deficiency (Glucose-6-Phosphate Dehydrogenase deficiency).

Populations Requiring Caution

Use of Furantin 100 requires caution and monitoring in several groups due to increased risk of toxicity:

• Elderly Patients: Due to the higher likelihood of reduced renal function.
• Comorbidities: Patients with diabetes mellitus, anemia, electrolyte imbalance, or Vitamin B deficiency are at enhanced risk for peripheral neuropathy and require careful consideration before use.
• Lactation: Use is not recommended when breastfeeding an infant younger than one month or an infant with known G6PD deficiency.

Interactions with Other Medicines and Products

This section outlines the officially documented interaction patterns for Nitrofurantoin, the active ingredient in Furantin 100, based on government regulatory information.

Pharmacokinetic and Substance Interactions

Interaction-Related Restrictions

Co-administration with quinolone antimicrobial agents is subject to caution based on a documented in vitro antagonism. The unfavorable pharmacokinetic changes resulting from co-administration with uricosuric drugs (Probenecid and Sulfinpyrazone) lead to restrictions on their combined use, compromising the drug's therapeutic action in the urinary tract while increasing systemic exposure. The medicine may also cause a false-positive reaction during specific urine glucose tests (using Benedict’s or Fehling’s solutions), which is a documented procedural interaction constraint.

Population Considerations

Interactions carry heightened significance in patients with Renal Impairment (e.g., CrCl < 60 mL/min or eGFR < 45 mL/min/1.73m^2), where reduced clearance increases systemic concentration and risk of toxicity.

How Furantin 100 Works

The unique action of Nitrofurantoin (Furantin 100) begins when the inactive molecule, a prodrug, is transported into the target bacteria. Inside the cell, specific bacterial enzymes called flavoproteins (nitroreductases) catalyze the reduction of the compound. This process generates highly unstable and reactive intermediate radicals that become the active agents of the antimicrobial mechanism.

The toxic intermediates proceed to indiscriminately attack and permanently alter multiple critical bacterial structures simultaneously. These targets include the bacterial DNA, which prevents replication; ribosomal proteins, which halts protein synthesis; and several metabolic enzymes, which stops energy production. The multi-site attack on vital components reduces the potential for bacterial resistance mediated by single-point target mutations.

The consequence of this molecular damage is a rapid arrest of bacterial growth (bacteriostasis) and, at sufficient concentrations, the active killing of the cells (bactericidal action). The therapeutic range of this mechanism is constrained because the required concentration levels are achieved only within the urinary system. This localization determines the physiological area where the mechanism can operate.

Administration Scope

Instruction Classifications (High-level)

Resulting Procedural Structure

Official step sequence:

• Intake Condition Check: Ensure the dose is ready to be taken with food or milk.
• Dose Administration (Acute): Administer the prescribed dose either four times daily (standard form) or twice daily (dual-release form).
• Dose Administration (Prophylaxis): Administer the prescribed dose once daily, typically at bedtime.
• Completion: Therapy for acute use typically lasts 7 days, and the full prescribed course must be completed.

Connection to the overall use protocol

The official administration protocol for Furantin 100 is defined by a mandatory oral route and a strict requirement for intake with food to regulate absorption. The total daily dosing is structured by the specific clinical purpose, requiring either a divided schedule for acute therapy or a single daily dose for suppressive regimens, with a non-negotiable duration for course completion.

Research Evidence / Overview of Studies for Furantin 100

This overview describes the scope of clinical research conducted on the active ingredient nitrofurantoin, focusing on the types of studies available and what they examined, consistent with authoritative regulatory reviews. This text does not offer medical advice or describe dosing, side effects, or clinical recommendations.

Evidence for Use in Acute Uncomplicated Cystitis (Lower UTI)

Research examined how Furantin 100 was studied for acute lower urinary tract infections (cystitis) primarily utilizing short-term Randomized Controlled Trials (RCTs) and Meta-analyses. These studies were studied for their relevance in trials assessing short-term or episodic symptom patterns. Researchers focused on two main outcomes: the confirmed eradication of the specific bacteria in the urinary tract (Microbiological Cure) and the complete disappearance of symptoms (Clinical Cure).

The initial core research primarily included Adult Women with bacteriologically confirmed infections. These trials were often set up to allow comparisons with other established antibacterial agents. Research describes that studies reported measurements of both the patterns of bacterial eradication and the course of symptomatic relief across these study populations over defined time intervals.

However, many of the foundational randomized trials are historical, dating back several decades. The documented observation periods were typically short-term, meaning there is limited information for long-term outcomes or the durability of the response beyond the immediate post-treatment follow-up period.

Evidence for Use in Preventing Recurrent UTIs (Prophylaxis)

Research explored the role of the medicine in the prevention, or prophylaxis, of recurrent UTIs, and this was evaluated in long-term Randomized Controlled Trials (RCTs). These studies were studied for their use in conditions characterized by fluctuating or episodic manifestations in susceptible individuals. Studies monitored Adult Women with a history of experiencing frequent UTIs, and trials often included a comparator group.

Studies explored key outcomes including the Recurrence Rate (how frequently new infections occurred over time) and the Time to First Recurrence. Findings describe patterns observed in the studies regarding the frequency of new infections during the defined observation periods (e.g., six months to a year).

The overall methodological quality of prophylactic trials was observed in some studies to be Poor to Fair, and scientific reviews note that evidence quality varies across studies; therefore, certainty surrounding these findings remains low.

Key Studies & References

1. What is the risk of peripheral neuropathy with nitrofurantoin (MACROBID)? - RxFiles (Used to support claims of historical studies and varying quality/bias)
2. Urinary tract infection (recurrent): antimicrobial prescribing (NICE Guideline)
3. Recurrent Urinary Tract Infections - StatPearls - NCBI Bookshelf (Used for pediatric and general population context)

Common questions about Furantin 100 (FAQ)

Q: What is Furantin 100 primarily used for?

According to the official product information, Furantin 100 is used to treat infections caused by bacteria, specifically those that are sensitive to the active substance, nitrofurantoin. Regulatory documents indicate that the medicine is primarily used to treat infections of the lower urinary tract, such as the bladder. Its mechanism involves stopping the growth of these susceptible bacteria.

Q: Is Furantin 100 an antibiotic?

Yes, Furantin 100 contains the active ingredient nitrofurantoin, which is classified in regulatory documents as an antibacterial agent. This means it is a type of antibiotic used to combat bacterial infections. Its action is targeted at controlling the growth of susceptible bacteria.

Q: Does Furantin 100 treat all types of infections?

No, official information states that Furantin 100 only treats infections caused by bacteria that are known to be sensitive to the medicine's active ingredient, nitrofurantoin. The medication is not effective against infections caused by viruses or fungi. It is primarily indicated for treating specific bacterial infections, particularly those affecting the lower urinary tract.

Q: What should I do if I miss a dose of Furantin 100?

Regulatory documents describe taking the forgotten dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the official product information indicates that the missed dose is typically skipped entirely. It is advised to then continue with the regular schedule and not take a double dose to compensate for the missed one.

Q: Can I stop taking Furantin 100 once my symptoms improve?

Official information emphasizes that the full course of treatment with Furantin 100 is typically completed, even if a person's symptoms begin to improve quickly. Stopping the medication too soon may increase the risk of the infection returning, or the bacteria may become resistant to the antibiotic. The length of treatment is determined by a healthcare professional.

Q: Does Furantin 100 need to be taken with food?

Regulatory documents state that Furantin 100 is generally advised to be taken with food. Taking the medicine with meals may help to increase the absorption of the active substance, which can contribute to its effectiveness. Official information also notes that taking it with food can help to reduce the chance of experiencing stomach upset or nausea.

Q: What if I accidentally take more Furantin 100 than recommended (overdose)?

Official product information advises that if an overdose of Furantin 100 is suspected, professional medical assistance should be sought immediately. Symptoms of an overdose are generally not well-defined, but immediate medical consultation is recommended in the official information. It is often helpful to bring the medicine packaging for reference.

Storage and Disposal Requirements for Furantin 100

Furantin 100 (nitrofurantoin) must be stored according to specific regulatory requirements to ensure its stability. The medicine must be kept at a temperature not exceeding 30°C.

Mandatory Conditions

Disposal Instructions

Unused or expired Furantin 100 must be managed as pharmaceutical waste. Dispose of the product in accordance with local requirements for unused medicines. The drug must not be disposed of via wastewater or general household trash.